Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

v3.24.1.u1
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
 1 Months Ended 3 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs     $ 15,000,000 $ 9,600,000  
Contingent consideration under RPAs, AAAs and CPPAs     3,000,000   $ 7,000,000
Short-term royalty and commercial payment receivables     9,819,000   14,215,000
Aronora | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item 5        
Non-royalties to be received (as a percent) 10.00%        
Future non-royalty payments to be received (as a percent) 5.00%        
Multiplier for cumulative amount of consideration paid 2        
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000,000.0 $ 3,000,000.0      
Threshold amount of cumulative royalties on net sales per product 250,000,000.0        
Maximum royalty milestone payments to be paid per product 85,000,000.0        
Acquisition of royalty and commercial payment receivables, Long-Term 9,000,000.0        
Contingent consideration under RPAs, AAAs and CPPAs 3,000,000.0        
Amount of allowance for credit losses     $ 0   $ 0
Aronora | Royalty Purchase Agreement | Minimum          
Agreements          
Threshold amount of cumulative royalties on net sales per product 25,000,000.0        
Aronora | Royalty Purchase Agreement | SVB Loan          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs $ 3,000,000.0        
Aronora | Royalty Purchase Agreement | Bayer Products          
Agreements          
Number of drug candidates | item 3        
Number of drug candidates subject to exclusive license option | item 1        
Royalties entity has right to receive (as a percent) 100.00%        
Non-royalties to be received (as a percent) 10.00%        
Contingent future cash payment for each product $ 1,000,000.0        
Aronora | Royalty Purchase Agreement | Bayer Products | Maximum          
Agreements          
Contingent consideration under RPAs, AAAs and CPPAs $ 3,000,000.0        
Aronora | Royalty Purchase Agreement | Non-Bayer Products          
Agreements          
Number of drug candidates 2        
Non-royalties to be received (as a percent) 10.00%